Oregon is one of a few states where methamphetamine (MA) abusers without a greater history of cocaine abuse are recruited for clinical research. This renewal of the Methamphetamine Abuse Research Center (MARC) will characterize effects of MA at molecular, genetic, neurochemical, anatomical, behavioral, and clinical levels, to identify risks and obstacles to recovery in MA abusers. Integrated preclinical and clinical research components use some common methodologies and address MA-related themes of neuroadaptation, neurocircuitry, and neuroimmune effects. This renewal continues to pursue bidirectional translational research in which human and animal results inform one another. The Center's Administrative Core 1 supervises budgetary issues and facilitates interactions among MARC investigators, and the Biostatistics and Genetics Core 2 provides statistical and genetic analysis services. The Animal Core 3 provides genetic animal models and some behavioral testing services to MARC investigators. The Education Core 4 coordinates the research training of M.D. and Ph.D. pre- and post-doctoral fellows, and disseminates clinical and preclinical information from MARC investigators to other Centers and more rural areas that are impacted by MA abuse. The Translational Service Core 5 recruits and characterizes subjects and conducts identical biochemical assays on human and MA drinking selected mouse line samples. The Pilot Projects Core 6 supports the development of multiple new directions in research on MA abuse. Scientific Component 7 associates image analysis results with impulsive decision making in human and animal subjects. Scientific Component 8 examines the role of immune function in human cognitive response and tests a novel immunotherapy in mice, and Scientific Component 9 uses MA drinking selected mouse lines to examine the role of immune function in the risk for MA self-administration and how this risk interacts with MA effects on immune function. Data and samples are shared and compared across components. Thus, the MARC addresses clinically relevant themes using integrated, innovative, multidisciplinary, and translational approaches.

Public Health Relevance

Recent studies indicate that the medical, social, legal, and occupational costs of MA abuse are over $2 billion dollars a year. This Methamphetamine Abuse Research Center will characterize medical, psychiatric, and genetic factors that contribute to MA abuse and impede recovery from drug withdrawal.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA018165-09
Application #
8882363
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Program Officer
Grant, Steven J
Project Start
2004-09-01
Project End
2017-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
9
Fiscal Year
2015
Total Cost
$1,648,585
Indirect Cost
$397,863
Name
Oregon Health and Science University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Shabani, Shkelzen; Schmidt, Bryan; Ghimire, Bikalpa et al. (2018) Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake. Genes Brain Behav :e12533
Eshleman, Amy J; Nagarajan, Shanthi; Wolfrum, Katherine M et al. (2018) Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (Berl) :
McCready, Holly; Kohno, Milky; Kolessar, Michael et al. (2018) Functional MRI and delay discounting in patients infected with hepatitis C. J Neurovirol 24:738-751
Loftis, Jennifer M; Valerio, Juno; Taylor, Jonathan et al. (2018) S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcohol Clin Exp Res :
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27-34
Tosh, Dilip K; Ciancetta, Antonella; Mannes, Philip et al. (2018) Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega 3:12658-12678
McCarty, Dennis; Priest, Kelsey C; Korthuis, P Todd (2018) Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annu Rev Public Health 39:525-541
Eastwood, Emily C; Eshleman, Amy J; Janowsky, Aaron et al. (2018) Verification of a genetic locus for methamphetamine intake and the impact of morphine. Mamm Genome 29:260-272
Kohno, Milky; Dennis, Laura E; McCready, Holly et al. (2018) A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend 192:186-192
Holton, Dwight; White, Elizabeth; McCarty, Dennis (2018) Public Health Policy Strategies to Address the Opioid Epidemic. Clin Pharmacol Ther 103:959-962

Showing the most recent 10 out of 143 publications